Pharma Bio Serv (PBSV) Upgraded by ValuEngine to Hold
ValuEngine upgraded shares of Pharma Bio Serv (OTCMKTS:PBSV) from a sell rating to a hold rating in a research report sent to investors on Thursday morning.
Shares of Pharma Bio Serv (OTCMKTS PBSV) opened at $0.56 on Thursday. The stock has a market capitalization of $12.91, a price-to-earnings ratio of -9.33 and a beta of 0.36. Pharma Bio Serv has a 12-month low of $0.33 and a 12-month high of $0.83.
Pharma Bio Serv (OTCMKTS:PBSV) last posted its earnings results on Monday, January 29th. The company reported ($0.02) earnings per share (EPS) for the quarter. The company had revenue of $3.63 million for the quarter. Pharma Bio Serv had a negative return on equity of 6.71% and a negative net margin of 9.08%. analysts forecast that Pharma Bio Serv will post -0.06 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/03/04/pharma-bio-serv-pbsv-upgraded-by-valuengine-to-hold.html.
Pharma-Bio Serv, Inc is a compliance and technology transfer services consulting company. The Company operates through four segments: Puerto Rico technical compliance consulting, United States technical compliance consulting, Europe technical compliance consulting, and Puerto Rico microbiological and chemical laboratory testing division (Lab).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Pharma Bio Serv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Bio Serv and related companies with MarketBeat.com's FREE daily email newsletter.